|
Cohort1: Reduced Lymphodepletion Dose
|
| Administration route |
infusion |
| Pts |
13 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
2/10(PR); 8/10(SD) |
| Adverse reactions |
5/13(All-cause mortality); 5/13(Blood and lymphatic system disorders; Cardiac disorders; Gastrointestinal disorders; Immune system disorders; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Respiratory, thoracic and mediastinal disorders) |
|
|
Cohort2: Standard Lymphodepletion Dose
|
| Administration route |
infusion |
| Pts |
10 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
4/10(PR); 1/10(PD); 5/10(SD) |
| Adverse reactions |
7/10(General disorders; Immune system disorders; Immune system disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders) |
|